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A two-stage explantation of a left ventricular assist device (LVAD) was performed on 47 year old afro-american
gentlemen with non-ischemic dilated cardiomyopathy (DCM) who was successfully bridged to recovery. After he
suffered a stroke caused by a VAD thrombosis with embolisation, the VAD outflow graft was first ligated using
minimally-invasive approach. Two months later, the device was explanted and a manufactured titanium plug was
placed into the sewing ring. This stepwise procedure might be beneficial in cases of high thromboembolic risk and
in patients who suffered a thromboembolic event previously.
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Ventricular assist devices (VADs) provide an established
mechanical support of patients with end-stage heart fail-
ure as bridge to transplantation, bridge to recovery and
chronic support [1].
However, successful LVAD explantation can only be
performed in a restricted number of patients who meet
the criteria of myocardial recovery [2,3]. In this respect,
our institution has reported encouraging results with
pharmacological therapy combined with continuous-
flow or pulsatile-flow LVADs as bridge to recovery [2,3].
The new miniaturized centrifugal HVAD® Pump
(HeartWare Inc, Framingham, MA) is a novel third gen-
eration VAD. One of the most significant design advan-
tages of the HeartWare HVAD Pump is its size,
intrapericardial placement and versatility in terms of im-
plant options [4]. Due to the miniaturized dimensions it
can be implanted over a minimal invasive approach
without sternotomy [5].* Correspondence: A.Sabashnikov@rbht.nhs.uk
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article, unless otherwise stated.Full sternotomy LVAD explantation is shown to be
feasible; however it might be associated with increased
risk of intraoperative bleeding, need for blood transfu-
sions and postoperative ventricular dysfunction. This
problem might be partially resolved by LVAD explant-
ation via minimally invasive lateral thoracotomy [6].
However, in cases of high thromboembolic risk, both ap-
proaches may lead to embolic stroke due to manipula-
tion and handling of LVAD during surgery. In this
report, we present our experience with staged LVAD ex-
plantation in a patient with myocardial recovery who
suffered an embolic stroke following LVAD thrombosis.
This approach was used with the view to preventing po-
tential flush of clots from the thrombosed LVAD redu-
cing the risk of further potential stroke.Case presentation
A 47-years-old afro-american gentleman diagnosed with
non-ischemic dilated cardiomyopathy (DCM) underwent
a continuous-flow LVAD (HeartWare) implantation as a
bridge to transplantation. Postoperatively, the device
flow was 6.6 L/min, left ventricular ejection fraction (EF)
was 16%, and the left ventricular systolic (LVESD) and
diastolic (LVEDD) diameters were 63 and 71 mm, re-
spectively. After an uncomplicated postoperative course,
the patient was discharged home. Six month later, hisntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 2 The outflow graft was ligated and transected.
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26 mm, LVEDD: 46 mm, EF: 63%). The exercise test ac-
cording to Modified Bruce Protocol [3] revealed that the
maximum volume of oxygen (VO2 max) on support was
almost constant at 2,700 rpm and 1,800 rpm. A trans-
thoracic echocardiogram (TTE) confirmed no serious
heart dilatation after 15 min of exercise. Due to these
evident signs of myocardial recovery the patient was ad-
mitted for an elective LVAD removal.
Unfortunately, he suffered a right fronto-parietal lobe
infarct a night before the elective operation. The main
areas of neurological impairment were left arm weak-
ness, language and attention. Suggesting a thrombotic
formation in the device and a displaced thrombus caus-
ing the stroke, three days after this event the LVAD was
stopped; the outflow graft (Figure 1) was ligated and cut
in between (Figure 2). This was done through a minia-
turized incision right parasternally at the level of the
third intercostal space. As clots occluding the outflow
graft were confirmed intraoperatively, the distal part of
the outflow graft was inspected and remaining clots
were removed. Subsequently, the patient participated in
a post-stroke rehabilitation program with progressive
recovery.
After two months, the LVAD pump was electively
explanted through median sternotomy in off-pump tech-
nique. A manufactured titanium plug was placed into
the inflow sewing ring which was left in place. Postoper-
ative examination of the pump confirmed a dense
thrombus formation with a soft red thrombus cast
around the impeller of the device. With a quick postop-
erative recovery, the patient was discharged home with
stable condition, satisfactory cardiac parameters and im-
proving neurological status. From the myocardial recov-
ery point of view, there have been no acute heart failureFigure 1 Access to the outflow graft through a miniaturized
incision right parasternally at the level of the third
intercostal space.symptoms, no orthopnea and no peripheral oedema over
6 months follow-up.
Discussion
The two-stage LVAD explantation in patients with myo-
cardial recovery and high risk of thromboembolic events
offers several advantages compared to the conventional
approach. The ligature of the VAD outflow graft through
a small intercostal incision might prevent thrombotic
flush from the VAD which can occur during extensive
dissections during conventional LVAD explantation.
Also, patients who already suffered an embolic stroke
might benefit from additional time for recovery from
previous stroke before LVAD is explanted. Furthermore,
such a stepwise approach might reduce intra- and post-
operative complications, such as right ventricular dys-
function and bleeding with the need for massive
transfusions.
In our case, the sewing ring of the LVAD was not re-
moved but was closed using a manufactured titanium
plug. As previously described, this approach may reduce
the risk of perioperative bleeding and infections [7].
Also, the operating time is shortened due to no need for
explantation of the ring and closing the left ventricle. It
also preserves the geometry of the left ventricle.
Previous research describes thrombolysis also as a suit-
able treatment of VAD thrombosis. However, performed
in emergency and in the setting of thrombolysis and
anticoagulation introduced for VAD thrombosis, it may
lead to severe bleeding complications. Furthermore, in
our particular case, the VAD explantation was the best
option due to recovery of myocardial function.
The risk of perioperative complications might be mini-
mized even more if the VAD explantation is also per-
formed without cardiopulmonary bypass [6]. This
technique might reduce the risk of infection,
hemodynamic instability, and can be done without
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bility of this approach should be considered in individual
cases dependent on topographical location and accessi-
bility of the LVAD.
Conclusion
The two-stage VAD explantation is a well reasonable
option in cases of high thromboembolic risk and in pa-
tients who suffered a thromboembolic event previously.
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